What are recommended brands of extended‑release metformin and sodium‑glucose cotransporter‑2 (SGLT2) inhibitors in India?

Brand Recommendations for Extended-Release Metformin and SGLT2 Inhibitors in India

For extended-release metformin in India, look for brands containing 500mg or 1000mg ER formulations that can be dosed once daily, with generic options being equally effective as branded versions. For SGLT2 inhibitors, prioritize empagliflozin (10-25mg), dapagliflozin (10mg), or canagliflozin (100-300mg) based on cardiovascular and renal benefits, with brand selection depending on local availability and cost.

Extended-Release Metformin Selection

Extended-release and immediate-release metformin formulations are equally effective with no consistent differences in side effect profiles 1. The key advantage of ER formulations is once-daily dosing, which improves adherence 1.

Dosing considerations:

• Start with 500mg ER once daily with the evening meal
• Titrate upward by 500mg weekly as tolerated
• Target dose: 1500-2000mg once daily (maximum 2000mg for most ER formulations) 1, 2
• Maximum approved daily dose varies by formulation but typically 2000mg for ER 3

Important prescribing points:

• Generic metformin ER is as effective as branded versions and significantly more cost-effective 4, 3
• In India, multiple pharmaceutical companies manufacture quality metformin ER formulations
• The specific brand matters less than ensuring the ER formulation and appropriate dosing

SGLT2 Inhibitor Selection

Prioritize agents with proven cardiovascular and renal benefits 2, 5, 6:

First-Line SGLT2 Inhibitors (in order of evidence strength):

1. Empagliflozin 10-25mg once daily

   • Proven reduction in cardiovascular death in patients with established CVD 5
   • Demonstrated heart failure benefits in both HFrEF and HFpEF 7
   • Renal protection benefits 2

2. Dapagliflozin 10mg once daily

   • Reduces hospitalization for heart failure and cardiovascular death 5, 7
   • Proven renal benefits in CKD patients 2, 8
   • Benefits extend to patients without diabetes 7

3. Canagliflozin 100-300mg once daily

   • Reduces major adverse cardiovascular events, MI, and stroke 5
   • Strong renal protection, especially in diabetic nephropathy 2
   • Caution: Higher amputation risk in patients with prior amputation or severe peripheral neuropathy 5

Practical Prescribing Algorithm:

If patient has established CVD or high cardiovascular risk:

• Choose empagliflozin or dapagliflozin as first-line 5, 6

If patient has CKD (eGFR 30-60 mL/min/1.73m² or albuminuria ≥200 mg/g):

• Choose canagliflozin, empagliflozin, or dapagliflozin 2, 9
• Continue even if eGFR falls below 30 unless dialysis initiated 2

If patient has heart failure (HFrEF or HFpEF):

• Empagliflozin or dapagliflozin strongly recommended 7, 8

Indian Market Considerations

Real-world evidence from India demonstrates that all SGLT2 inhibitors (canagliflozin, empagliflozin, dapagliflozin, and remogliflozin) show comparable efficacy in reducing HbA1c (approximately 1% reduction), body weight (2-3 kg reduction), and blood pressure 10, 11.

Brand availability in India:

• Multiple Indian pharmaceutical companies manufacture these agents
• Fixed-dose combinations with metformin are available and may improve adherence 12, 13
• Cost considerations favor generic formulations when available

Critical Safety Considerations

Before initiating SGLT2 inhibitors:

• Check eGFR (avoid initiation if <30 mL/min/1.73m² for glycemic control, but continue for cardio-renal benefits if already established) 2, 5
• Assess volume status and consider reducing diuretics 2
• Educate about genital mycotic infections (10-15% risk in women) 8

Withhold SGLT2 inhibitors during:

• Prolonged fasting or surgery (3-4 days before) 2, 6
• Critical illness or severe dehydration 2
• Risk of diabetic ketoacidosis 6

Common pitfalls to avoid:

• Don't discontinue SGLT2 inhibitors solely due to temporary eGFR decline (up to 15% reduction is expected and typically resolves) 2, 8
• Don't use canagliflozin in patients with prior amputation or severe peripheral neuropathy 5
• Don't forget to reduce insulin or sulfonylurea doses when adding SGLT2 inhibitors to prevent hypoglycemia 2

Combination Therapy Approach

Metformin + SGLT2 inhibitor is the preferred initial combination for most patients with type 2 diabetes and cardiovascular/renal risk factors, independent of baseline HbA1c 6, 14. This combination can be initiated simultaneously in appropriate high-risk patients rather than waiting for metformin monotherapy failure 6.